ScreenerHero

WHWKWhitehawk Therapeutics Inc. Common Stock

NAS · US · Healthcare · Biotechnology · ir.whitehawktx.com
4.730USD-2.87%Mkt Cap: 269.65M $P/E: —

Whitehawk Therapeutics, Inc., a clinical-stage oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments. It provides three next generation antibody drug conjugates (ADC) p…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap269.65M $
Enterprise Value85.37M $
Revenue (TTM)0 $
Gross Profit6.38M $
Net Income (TTM)-20.60M $
Revenue/Share0.0000 USD
Last Price4.730 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees32
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-4.90
PEG—
EV/EBITDA-0.99
EV/Revenue—
P/SInfinity
P/B1.96
EPS (TTM)-1.20
EPS (Forward)-0.99
52W Range
1.57081% of range5.495
52W High5.495 USD
52W Low1.570 USD
Profitability
Gross Margin89.36%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin-288.26%
ROE-15.11%
ROA-13.66%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-97.43M $
CapEx (TTM)552.00K $
FCF Margin—
FCF Yield-16.17%
Net Debt-189.98M $
Net Debt/EBITDA2.21
Balance Sheet
Debt/Equity0.00
Current Ratio17.38
Quick Ratio17.16
Book Value/Sh2.462 USD
Cash/Share3.332 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:15
Split DateAug 27, 2021
Analyst Consensus
Rating1.9 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)7.500 USD
Upside (mean)+58.6%
Target Range4.000 USD – 10.00 USD
$4.000+58.6% to mean$10.00
# Analysts6
Ownership
Shares Out.57.01M
Float28.74M
Insiders12.62%
Institutions76.04%
Short Interest
Short Ratio8.9d
Short % Float12.54%
Short % Out.7.77%
Shares Short4.43M
Short (prev mo.)2.83M
Technical
SMA 504.183 (+13.1%)
SMA 2003.469 (+36.4%)
Beta0.78
S&P 52W Chg18.16%
Avg Vol (30d)430.59K
Avg Vol (10d)426.35K
Technical Indicators
RSI (14)60.7
MACD0.1967
MACD Signal0.1395
MACD Hist.+0.0572
BB Upper5.159 USD
BB Middle4.261 USD
BB Lower3.363 USD
BB Width42.13%
ATR (14)0.2977 USD
Vol Ratio (20d)0.48x